» Articles » PMID: 36229842

CTpathway: a CrossTalk-based Pathway Enrichment Analysis Method for Cancer Research

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2022 Oct 13
PMID 36229842
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pathway enrichment analysis (PEA) is a common method for exploring functions of hundreds of genes and identifying disease-risk pathways. Moreover, different pathways exert their functions through crosstalk. However, existing PEA methods do not sufficiently integrate essential pathway features, including pathway crosstalk, molecular interactions, and network topologies, resulting in many risk pathways that remain uninvestigated.

Methods: To overcome these limitations, we develop a new crosstalk-based PEA method, CTpathway, based on a global pathway crosstalk map (GPCM) with >440,000 edges by combing pathways from eight resources, transcription factor-gene regulations, and large-scale protein-protein interactions. Integrating gene differential expression and crosstalk effects in GPCM, we assign a risk score to genes in the GPCM and identify risk pathways enriched with the risk genes.

Results: Analysis of >8300 expression profiles covering ten cancer tissues and blood samples indicates that CTpathway outperforms the current state-of-the-art methods in identifying risk pathways with higher accuracy, reproducibility, and speed. CTpathway recapitulates known risk pathways and exclusively identifies several previously unreported critical pathways for individual cancer types. CTpathway also outperforms other methods in identifying risk pathways across all cancer stages, including early-stage cancer with a small number of differentially expressed genes. Moreover, the robust design of CTpathway enables researchers to analyze both bulk and single-cell RNA-seq profiles to predict both cancer tissue and cell type-specific risk pathways with higher accuracy.

Conclusions: Collectively, CTpathway is a fast, accurate, and stable pathway enrichment analysis method for cancer research that can be used to identify cancer risk pathways. The CTpathway interactive web server can be accessed here http://www.jianglab.cn/CTpathway/ . The stand-alone program can be accessed here https://github.com/Bioccjw/CTpathway .

Citing Articles

Molecular principles underlying aggressive cancers.

Nussinov R, Yavuz B, Jang H Signal Transduct Target Ther. 2025; 10(1):42.

PMID: 39956859 PMC: 11830828. DOI: 10.1038/s41392-025-02129-7.


ssMutPA: single-sample mutation-based pathway analysis approach for cancer precision medicine.

He Y, Lai J, Wang Q, Pan B, Li S, Zhao X Gigascience. 2024; 13.

PMID: 39704703 PMC: 11659979. DOI: 10.1093/gigascience/giae105.


Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia.

Saettini F, Guerra F, Mauri M, Salter C, Adam M, Adams D J Clin Immunol. 2024; 45(1):15.

PMID: 39312004 DOI: 10.1007/s10875-024-01793-8.


Integrative network analysis of transcriptomics data reveals potential prognostic biomarkers for colorectal cancer.

Mahajan M, Sarkar A, Mondal S Cancer Med. 2024; 13(11):e7391.

PMID: 38872418 PMC: 11176588. DOI: 10.1002/cam4.7391.


PheSeq, a Bayesian deep learning model to enhance and interpret the gene-disease association studies.

Yao X, Ouyang S, Lian Y, Peng Q, Zhou X, Huang F Genome Med. 2024; 16(1):56.

PMID: 38627848 PMC: 11020195. DOI: 10.1186/s13073-024-01330-7.


References
1.
Sondka Z, Bamford S, Cole C, Ward S, Dunham I, Forbes S . The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018; 18(11):696-705. PMC: 6450507. DOI: 10.1038/s41568-018-0060-1. View

2.
Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

3.
Liao Y, Wang J, Jaehnig E, Shi Z, Zhang B . WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019; 47(W1):W199-W205. PMC: 6602449. DOI: 10.1093/nar/gkz401. View

4.
Blalock E, Geddes J, Chen K, Porter N, Markesbery W, Landfield P . Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004; 101(7):2173-8. PMC: 357071. DOI: 10.1073/pnas.0308512100. View

5.
Burotto M, Chiou V, Lee J, Kohn E . The MAPK pathway across different malignancies: a new perspective. Cancer. 2014; 120(22):3446-56. PMC: 4221543. DOI: 10.1002/cncr.28864. View